Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meditoxin injection for recurrence prevention in chronic sialoadenitis
KCT0004028Phase 4Completed
- Sponsor
- Medytox Inc.
- Start
- Jan 2019
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of Meditoxin in sialadenitis, sponsored by Medytox Inc. Primary endpoints: Recurrence prevention of chronic sialoadenitis and Safety of Meditoxin injections. Started Jan 2019; status: completed.
02
Drugs
Meditoxin
03
Conditions
sialadenitis
Beyond the preview
Go deeper on KCT0004028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004028.